Product Introduction: GLIMP M1 SR

GLIMP M1 SR is a widely prescribed combination antidiabetic medication manufactured by Biochem. Composed of 1mg of Glimepiride (a sulfonylurea) and 500mg of Metformin Hydrochloride Sustained-Release (SR), it is indicated for glycemic control in adult patients diagnosed with Type 2 Diabetes Mellitus. When used alongside a balanced diet and regular physical exercise, it helps regulate blood glucose levels.

Primary Indications

• Management of Type 2 Diabetes Mellitus in adults for optimal glycemic control.
• Improving insulin secretion and restricting hepatic glucose production.
• Preventing post-prandial blood glucose spikes and stabilizing fasting blood sugar levels.

Clinical Benefits

• HbA1c Optimization: Assists in achieving and maintaining target HbA1c (glycosylated hemoglobin) levels.
• Dual Action: Glimepiride stimulates insulin secretion from the pancreas, while Metformin improves insulin sensitivity.
• Sustained-Release Metformin: Smooth, gradual drug release minimizes gastrointestinal side effects.

Possible Side Effects

Common side effects may include:

• Gastrointestinal issues (nausea, metallic taste, abdominal bloating, transient diarrhea).
• Hypoglycemia (low blood sugar), especially when co-administered with sulfonylureas or insulin.
• Dizziness, headache, or mild fatigue.

How to Take GLIMP M1 SR

• Take the tablet daily, with or immediately after your morning meal to minimize stomach upset and prevent hypoglycemia.
• Swallow the tablet whole with a glass of water. Do not crush, chew, or split.
• Do not stop taking the drug abruptly without consulting your endocrinologist.

Mechanism of Action

GLIMP M1 SR works through two distinct mechanisms:

• Glimepiride: Binds to ATP-sensitive potassium channels on pancreatic beta-cells, causing depolarization and opening of calcium channels. This triggers the release of insulin.
• Metformin: Decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake.

Safety Warnings

• Lactic Acidosis: Metformin carries a rare but serious risk of lactic acidosis. Avoid in severe renal impairment.
• Pregnancy & Nursing: Not recommended; insulin is typically the preferred therapy during pregnancy.
• Alcohol: Avoid excessive alcohol as it increases the risk of lactic acidosis and hypoglycemia.

Patient Advice

• Always carry a rapid-acting source of sugar (like glucose powder or fruit juice) in case of hypoglycemia.
• Monitor your blood glucose levels regularly as advised by your doctor.
• Adhere to a structured diet and exercise plan for optimal therapeutic outcomes.

Fact Box

Drug Interactions

• Corticosteroids: May increase blood glucose levels, reducing drug efficacy.
• Beta-Blockers: May mask the warning symptoms of hypoglycemia (tachycardia).
• Iodinated Contrast Media: Increased risk of lactic acidosis; hold Metformin temporarily.

User Feedback

• Patients report excellent control of their fasting and post-meal sugar levels, with a significant drop in HbA1c.
• Initial stomach bloating is common but typically fades away after 7 to 10 days of consistent use.